Ogalvibart/C 144LS
Alternative Names: Anti-SARS-CoV-2 mAbs - Bristol Myers Squibb; BMS-986414+BMS-986413; BMS-986414/C 144LS; C 144LS/BMS-986414; C 144LS/IM051; C 144LS/ogalvibart; C-135-LS/C-144-LS; C-144-LS/C-135-LS; COVID-19 mAbs - Bristol Myers Squibb; IM051/C 144LS; Monoclonal antibody duo - Bristol Myers Squibb; SARS-CoV-2 neutralising monoclonal antibody combination - Bristol Myers SquibbLatest Information Update: 11 Aug 2023
At a glance
- Originator Rockefeller University
- Developer National Institute of Allergy and Infectious Diseases; Rockefeller University; Xencor
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (Inhalation) (NCT04518410)
- 02 Aug 2022 Rockefeller University completes a phase I trial (In volunteers) in COVID-2019 infections (IV, SC) in USA (NCT04700163)
- 10 Mar 2022 Bristol-Myers Squibb completes enrolment in its phase II trial for COVID-2019 infections (Prevention) in the US (Bristol-Myers Squibb 10-K, December 2021)